•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., reminded investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). The action is pending in the United States District Court for the Central District of California.
Investors who purchased ImmunityBio securities and want to discuss their legal rights and how the case may affect their ability to recover for economic loss may contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email [email protected], or visit https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. To serve as lead plaintiff, a petition must be filed with the Court by May 26, 2026.
ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, in violation of federal securities laws.
On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public. The letter stated that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act.
The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”
Following the news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.
The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
